



ORACLE

ClearTrial 5.9 Release Supplemental Documentation

Support for Complex Trial Designs

Presented by Kristin Ludwig
Principal Solution Consultant
Oracle Health Sciences Global Business unit (HSGBU)

Safe Harbor Statement

The following is intended to outline our general product direction. It is intended for information purposes only and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, timing, and pricing of any features or functionality described for Oracle's products may change and remains at the sole discretion of Oracle Corporation.

ClearTrial 5.9 Themes

- **Support multiple cohorts (26) with different enrollment characteristics**
- **Support long-term follow-up periods for non-terminating endpoints**
- **Consolidation of Investigator grant/payment-specific assumptions in one place**
- **New Milestone Dates (FSFV-LSLV)**
- **End of Study Planning Update**
- **Work Breakdown Structure (WBS) Updates**
 - Medical Monitoring
 - Project Management
 - Site Management
 - Data Management Task updates
 - End of Study (EOS) DB Lock, Stat Report, Final report
 - eTMF support
- **Increased usability for a more efficient user experience**

ClearTrial 5.9 UI Changes – Subject Assumptions < 5.8 Cost Model

OLD User Interface Design

- **# of subjects** per location on the **LOCATIONS TAB**
- **Average grant per subject (\$)** per location on the **LOCATIONS TAB**
- Only **one cohort** is supported per study plan, per location on the **SUBJECT TAB**
- **Enrollment Period, Enrollment Distribution**, are per study plan, per location on the **SUBJECT TAB**
- **Screening** and **Drops** are per study plan, per location on the **SUBJECT TAB**
- Model up to **5 Treatment Arms** on the **TREATMENT TAB**

The image displays three overlapping screenshots of the Oracle ClearTrial 5.9 user interface, illustrating the changes in the Subject Assumptions < 5.8 Cost Model.

LOCATIONS TAB: This screenshot shows the 'Edit Plan' interface for 'Med Device Pivotal ballpark v1 for Medical Device Pivotal Study (device 10100)'. The 'LOCATIONS TAB' is highlighted. It displays a table with columns: Location, Sites, Subjects, Avg Grant/Subject, MOH/FDA Delay, and FSA Date. The table lists two locations: Canada (10 sites, 100 subjects, 4,500.00 USD) and USA (25 sites, 250 subjects, 4,500.00 USD).

SUBJECT TAB: This screenshot shows the 'Edit Plan' interface for the same study. The 'SUBJECT TAB' is highlighted. It displays the 'Define the Enrollment Period' section, including fields for Project Activity Start Date (12/1/20), First subject enrolled date (2/15/21), Last subject enrolled date (1/20/22), and Enrollment period (30 weeks).

TREATMENT TAB: This screenshot shows the 'Edit Plan' interface for the same study. The 'TREATMENT TAB' is highlighted. It displays the 'Study Characteristics' section, including fields for Trial Design (Parallel), Will there be an electronic subject diary? (Yes), and Last subject out date (1/27/24). It also shows a table for 'Treatment(s)' with columns: ID, Number of subjects, Treatment duration, SRE pages per subject, Subject diary pages, Lab and diagnostic tests per subject, Visits per subject, QOL pages, Pharmacoeconomic pages, and Cohort escalation reviews.

5.9 User Interface Enhancements

NEW User Interface Design

- **Subjects** will be spread across locations by default according to the ratio of sites in that location to the total number of sites. Override the default spread by **editing each treatment/cohort** on the **TREATMENT TAB**
- All **Investigator grant/payment** related assumptions are entered in **one centralized location** on the **TREATMENT TAB**
- Model up to **26 staggered cohorts** on the **TREATMENT TAB**
- **Enrollment Period, Enrollment Distribution** are per location, per cohort on the **TREATMENT TAB**

ORACLE
CLEARTRIAL CLOUD SERVICE

Kristin's Plan for 5.9 Release Slides for Kristin's Study (K Product)
Phase III / Protocol ID: Kristin's Study
Indication: Oncology / Solid Tumor

This plan is using the 5.9 cost model
This plan is using custom fields, version 336

EditReportMaintainAdminHelp

Welcome, Kristin Ludwig | Visit Oracle Help Center | Logout

Create Plan

OverviewLocationsSiteTreatmentDataMonitoringProviderMeetingsAssignmentLaborCostsPaymentsSummaryReports

Study Characteristics

Trial Design: ParallelCrossoverMeasure enrollment periods in: weeksMeasure treatment duration in: weeks

Investigator Grants

Location	Avg Grant/Subject	Stipend/Enrolled Subject	Payment/Screen Failure	% Screen Failures Paid	Stipend/Screen Failure
(Default)	0.00USD	0.00USD	0.00USD	0.00%	0.00USD
Canada	0.00USD	0.00USD	0.00USD	0.00%	0.00USD
USA	0.00USD	0.00USD	0.00USD	0.00%	0.00USD

Treatment(s)

AddEditCopyDelete

	Screening	Treatment	Follow-Up	
<input checked="" type="checkbox"/> Treatment A	Screening period: 1 weeks Enrolled subjects: <input type="text"/> FSFT/FPFT Date: --- Enrollment period: --- Enrollment rate: s/s/m Enrollment distribution: Acute LSFT/LPFT Date: --- LSLT/LPLT Date: ---	Screening visits per subject: 1 CRF pages/screened subject: 6 Screen failure rate: 9.09% Number of subjects to screen: 0	Treatment duration: weeks Visits per subject: <input type="text"/> CRF pages per subject: <input type="text"/> Number of cycles: 1 Subject diary pages: 0 QOL pages: 0 Pharmacoeconomic pages: 0 Subject drop rate: 17.00%	Follow subjects for: 4 weeks % completed subjects followed: 100.00% First follow-up occurs after: 4 weeks Follow-up visits occur every: 4 weeks Follow-up drop rate: 37.00% CRF pages per follow-up visit: <input type="text"/> Subject diary pages per visit: 0 QOL pages per visit: 0

Total Subjects: 0

CloseSaveNext



5.9 Treatment Tab TRIAL DESIGN CONSIDERATIONS

- If all subjects will be on the same duration of treatment, with the same visit schedule you will only plan for 1 treatment group/cohort for all subjects.
- If subjects will have different enrollment characteristics, treatment durations, or different visit schedules, you will be able to plan these by creating multiple treatment groups/cohorts.

If you need more than one treatment group/cohort, you can click “Add” and define a different treatment group’s parameters

Each treatment group/cohort is separated out into segments for general, screening, treatment and follow-up assumptions

Change the FSFT Date for those treatment groups/cohorts that start later than the first

When you have multiple treatment groups defined, click on any of the visible fields per segment to expand it to see ALL of the assumptions

Treatment(s)

Add

Edit

Copy

Delete

	Screening	Treatment	Follow-Up
<input type="checkbox"/> Dose A	<div>Screening period: 4 weeks</div> <div>Enrolled subjects: 79</div> <div>FSFT/FPFT Date: 07/24/24</div> <div>Enrollment period: 45 weeks</div>	<div>Treatment duration: 90 weeks</div> <div>Visits per subject: 10</div> <div>CRF pages per subject: 129</div> <div>Number of cycles: 1</div> <div>Subject diary pages: 0</div> <div>QOL pages: 0</div> <div>Pharmacoeconomic pages: 0</div> <div>Subject drop rate: 16.00 %</div>	<div>Follow subjects for: 4 weeks</div> <div>% completed subjects followed: 100.00 %</div> <div>First follow-up occurs after: 4 weeks</div> <div>Follow-up visits occur every: 4 weeks</div>
<input type="checkbox"/> Dose B	<div>Screening period: 4 weeks</div> <div>Enrolled subjects: 79</div> <div>FSFT/FPFT Date: 09/24/24</div> <div>Enrollment period: 45 weeks</div>	<div>Treatment duration: 90 weeks</div> <div>Visits per subject: 10</div> <div>CRF pages per subject: 129</div> <div>Number of cycles: 1</div> <div>Subject diary pages: 0</div> <div>QOL pages: 0</div> <div>Pharmacoeconomic pages: 0</div> <div>Subject drop rate: 16.00 %</div>	<div>Follow subjects for: 4 weeks</div> <div>% completed subjects followed: 100.00 %</div> <div>First follow-up occurs after: 4 weeks</div> <div>Follow-up visits occur every: 4 weeks</div>
<div>Total Subjects: 158</div> <div>PASD: 05/01/24</div> <div>FSFV: 06/26/24</div> <div>LSFT: 08/04/25</div> <div>FSLT: 04/14/26</div> <div>LSLT: 04/25/27</div> <div>FSLV: 06/09/26</div> <div>LSLV: 06/20/27</div>			



5.9 Treatment Tab Updates – Number of Cycles for Oncology Trials

Treatment "Dose A" - Note that some assumptions, such as duration, number of pages, and visits, are per cycle, not per treatment.

Subjects: 800	Screening period: 1 days	Cycle duration: 60 days	Follow-up visits occur every: 0 days
Screening visits per subject: 1	Visits per subject: 60	Follow subjects for: 40 days	% completed subjects followed: 100.00 %
CRF pages/screened subject: 5	Number of bednights: 60	First follow-up occurs after: 2 days	Follow-up visits occur every: 0 days
Screen failure rate: 50.00 %	CRF pages per subject: 80		
Screening period: 4 days	Number of cycles: 2 ⓘ		
Screening visits per subject: 4	Subject diary pages: 1		
CRF pages/screened subject: 12	QOL pages: 1		
Screen failure rate: 20.00 % ⚠	Pharmacoeconomic pages: 20		

If your oncology protocol includes more than one cycle, enter it here and note that the duration, CRF pages, and visits are per cycle, as specified in the message displayed when you click on the icon

1,800 PASD: 06/16/21 FSFV: 08/07/21 LSFV: 09/07/21 FSFT: 08/11/21 LSFT: 09/08/21 FSLT: 12/08/21 LSLT: 01/05/22 FSLV: 12/08/21 LSLV: 01/05/22



5.9 Treatment Tab Updates

TIP!

Click “Edit” to manage assumptions per treatment group/cohort, per location, and align the subject visit schedule to the Protocol’s Schedule of Assessments

#2
You now have the ability to define the Screening (Run in) period

#3
You will then enter the treatment or cycle duration (wks/days), # of treatment visits and # of CRFs per subject for the treatment period

#4
You will then enter the duration of the follow-up period (Days or Weeks)

#1
You will start by entering the # of Subjects per treatment group/cohort.

#5
You will define when the follow-up period begins, the average frequency of the visits and the average # of CRFs/Subject for the follow-up period.

Treatment(s)

AddEditCopy

	Screening	Treatment	Follow-Up	
<input checked="" type="checkbox"/> Treatment A	Screening period: 1 weeks Enrolled subjects: <input type="text"/> FSFT/FPFT Date: -- -- Enrollment period: -- -- Enrollment rate: s/s/m Enrollment distribution: Acute LSFT/LPFT Date: -- -- LSLT/LPLT Date: -- --	Screening visits per subject: 1 CRF pages/screened subject: 6 Screen failure rate: 9.09 % Subjects to screen: 0	Treatment duration: <input type="text"/> weeks Visits per subject: <input type="text"/> CRF pages per subject: <input type="text"/> Number of cycles: 1 Subject diary pages: 0 QOL pages: 0 Pharmacoeconomic pages: 0 Subject drop rate: 17.00 %	Follow subjects for: 4 weeks % completed subjects followed: 100.00 % First follow-up occurs after: 4 weeks Follow-up visits occur every: 4 weeks Follow-up drop rate: 37.00 % CRF pages per follow-up visit: <input type="text"/> Subject diary pages per visit: 0 QOL pages per visit: 0



5.9 Treatment Tab Updates

Once you enter the #of Subjects, ClearTrial will default the global FSFT date, and enrollment period and enrollment distribution assumptions. You may revise these defaults as needed

% completed subjects followed:
This value allows you to enter the % of subjects expected to complete treatment that will enter follow-up

ClearTrial defaults a safety follow-up that all completed subjects will enter 4 weeks after treatment intervention

Treatment A

Enrolled subjects: 100

FSFT/FPFT Date: 04/23/21

Enrollment period: 18 weeks

Enrollment rate: 1.33 s/s/m

Enrollment distribution: Acute

LSFT/LPFT Date: 08/26/21

LSLT/LPLT Date: 02/23/22

Screening

Screening period: 1 weeks

Screening visits per subject: 1

CRF pages/screened subject: 6

Screen failure rate: 9.09 %

Number of subjects to screen: 110

Treatment

Treatment duration: 26 weeks

Visits per subject: 6

CRF pages per subject: 100

Number of cycles: 1

Subject diary pages: 0

QOL pages: 0

Pharmacoeconomic pages: 0

Subject drop rate: 17.00 %

Monitoring minutes per page: 8.372

Follow-Up

Follow subject for: 4 weeks

% completed subjects followed: 100.00 %

First follow-up occurs after: 4 weeks

Follow-up visits occur every: 4 weeks

Follow-up drop rate: 37.00 %

CRF pages per follow-up visit:

Subject diary pages per visit: 0

QOL pages per follow-up visit:

Pharmacoeconomic pages per follow-up visit:

Total Subjects: 100

PASD: 01/01/21

PSFV: 04/16/21

LSFV: 08/19/21

FSFT: 04/23/21

LSFT: 08/26/21

FSLT: 10/21/21

LSLT: 02/23/22

PSLV: 10/21/21

LSLV: 02/23/22



5.9 Treatment Tab Updates – System Calculated Milestones

Treatment A

Enrolled subjects: 100

FSFT/FPFT Date: 04/23/21

Enrollment period: 18 weeks

Enrollment rate: 1.33 s/s/m

Enrollment distribution: Acute

LSFT/LPFT Date: 08/26/21

LSLT/LPLT Date:

Screening period: 1 weeks

Screening visits per subject: 1

CRF pages/screened subject: 6

Screen failure rate: 9.09 %

Number of subjects to screen: 110

Treatment duration: 26 weeks

Visits per subject: 6

CRF pages per subject: 100

Number of cycles: 1

Subject diary pages: 0

QOL pages: 0

Pharmacoeconomic pages: 0

Subject drop rate: 17.00 %

Monitoring minutes per page: 8.372

Follow subjects for: 4 weeks

% completed subjects followed: 100.00 %

First follow-up occurs after: 4 weeks

Follow-up visits occur every: 4 weeks

Follow-up drop rate: 37.00 %

CRF pages per follow-up visit:

Subject diary pages per visit: 0

QOL pages per visit: 0

Pharmacoeconomic pages/visit: 0

Total Subjects: 100

PASD: 01/01/21

FSFV: 04/16/21

LSPV: 08/19/21

FSFT: 04/23/21

LSFT: 08/26/21

FSLT: 10/21/21

LSLT: 02/23/22

FSLV: 10/21/21

LSLV: 02/23/22

TIP!
When you are distributing subjects across more than one treatment arm, this value will automatically update the Total Number of Subjects to be Enrolled

You will see the total number of subjects allocated and global key milestone dates across all treatments/cohorts in the new summary bar



5.9 Treatment Tab Updates – System Calculated Milestones

PASD: 01/01/21	FSFV: 04/16/21	LSFV: 08/19/21	FSFT: 04/23/21	LSFT: 08/26/21	FSLT: 10/21/21	LSLT: 02/23/22	FSLV: 10/21/21	LSLV: 02/23/22
----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------

System Defined Milestone Dates – Definitions:

- **PASD:** Project Activity Start Date (*entered on the OVERVIEW TAB*)
- **FSFV:** First Subject First Visit (*First Subject Screening/Enrollment Visit*)
- **LSFV:** Last Subject First Visit (*Last Subject Screening/Enrollment Visit*)
- **FSFT:** First Subject First Treatment (<5.8 Milestone: FSI)
- **LSFT:** Last Subject First Treatment (<5.8 Milestone: LSI)
- **FSLT:** First Subject Last Treatment
- **LSLT:** Last Subject Last Treatment
- **FSLV:** First Subject Last Visit (<5.8 Milestone: FSO)
- **LSLV:** Last Subject Last Visit (<5.8 Milestone: LSO)

If the screening period is not defined or if there will be no data collected during screening, this visit will be the same as the First Subject First Treatment (FSFT) date

If the screening period is not defined or if there will be no data collected during screening, this visit will be the same as the Last Subject First Treatment (LSFT) date

If there is no follow-up expected this date will be the same as the FSLT date

If there is no follow-up expected this date will be the same as the LSLT date



5.9 Treatment Tab Updates

TIP!
By defining the first Treatment Group you can save time by copying the first treatment and only changing those values that are different between treatment groups

Treatment(s)

Add

Edit

Copy

Delete

	Screening	Treatment	Follow-Up
<input type="checkbox"/> Treatment A	<div>Screening period: 1 weeks</div> <div>Screening visits per subject: 1</div> <div>CRF pages/screened subject: 6</div> <div>Screen failure rate: 9.09 %</div> <div>Number of subjects to screen: 110</div>	<div>Treatment duration: 26 weeks</div> <div>Visits per subject: 6</div> <div>CRF pages per subject: 100</div> <div>Number of cycles: 1</div> <div>Subject diary pages: 0</div> <div>QOL pages: 0</div> <div>Pharmacoeconomic pages: 0</div> <div>Subject drop rate: 17.00 %</div>	<div>Follow subjects for: 4 weeks</div> <div>% completed subjects followed: 100.00 %</div> <div>First follow-up occurs after: 4 weeks</div> <div>Follow-up visits occur every: 4 weeks</div> <div>Follow-up drop rate: 37.00 %</div> <div>CRF pages per follow-up visit:</div> <div>Subject diary pages per visit: 0</div> <div>QOL pages per visit: 0</div>
<input type="checkbox"/> Treatment B	<div>Screening period: 1 weeks</div> <div>Screening visits per subject: 1</div> <div>CRF pages/screened subject: 6</div> <div>Screen failure rate: 9.09 %</div> <div>Number of subjects to screen: 110</div>	<div>Treatment duration: 26 weeks</div> <div>Visits per subject: 6</div> <div>CRF pages per subject: 100</div> <div>Number of cycles: 1</div> <div>Subject diary pages: 0</div> <div>QOL pages: 0</div> <div>Pharmacoeconomic pages: 0</div> <div>Subject drop rate: 17.00 %</div>	<div>Follow subjects for: 4 weeks</div> <div>% completed subjects followed: 100.00 %</div> <div>First follow-up occurs after: 4 weeks</div> <div>Follow-up visits occur every: 4 weeks</div> <div>Follow-up drop rate: 37.00 %</div> <div>CRF pages per follow-up visit:</div> <div>Subject diary pages per visit: 0</div> <div>QOL pages per visit: 0</div>

Total Subjects:

200

PASD: 01/01/21

FSFV: 04/16/21

LSFV: 08/19/21

FSFT: 04/23/21

LSFT: 08/26/21

PSLT: 10/21/21

LSLT: 02/23/22

PSLV: 10/21/21

LSLV: 02/23/22

With a Parallel Study Design with two treatment groups on two different durations of treatment or different treatment schedules – the FPI date will stay the same



5.9 Complex Trial Planning Support

Supports Planning of Complex Trial Types including

- Multiple Treatment Groups/Cohorts (up to 26 groups)
- Dose Escalation trials or Expansion trial designs
- Adaptive Trials (where subjects treatment/follow-up durations may change)
- Extension Trials (that require ability to define long term follow-up)
- Umbrella/Bucket Trials (where subjects may continue treatment from a prior study that require multiple treatment/follow-up schedules)

5.9 Complex Trial Planning Support

Supports Supplemental CSR for Studies with Long Term Follow-up Periods

- **DATA TAB:** We now support the ability to have an initial DB lock and submission based on all the Subject Treatment data collected and including a Supplemental CSR for all the Subject Follow-up data collected.
- **DEFAULT by Design:** ClearTrial includes a standard 30-day safety follow-up after LSLT, so supplemental regulatory submissions are included by default. If these are not required for your particular trial design – see instructions below.

5.9 Complex Trial Planning Support

If **NO** supplemental CSR is planned (Guidance)

- If no supplemental CSR is planned for your study, you will need to modify the default assumptions of your template or plan to reflect “No” supplemental CSR on the Data tab.
- If a follow-up period is planned, but only 1 database lock for all subject data collected during treatment and follow-up, then you must adjust the # of days until DB lock to reflect the appropriate time from LSLV (Last Subject Last Visit) to DB Lock (+35 days)
- OR
- You can decide to include your follow-up period in your treatment period and indicate no follow-up period on the Treatment tab, and then you will not need to adjust the # of days until DB lock on the Data Tab.

5.9 Treatment Tab – Guidance If No Supplemental CSR is needed

Overview

Locations

Site

Treatment

Data

Monitoring

Provider

Meetings

Assignment

Labor

Costs

Payments

Summary

Reports

Serbia

3

South Africa

2

1,200.00

USD

100.0

1,200.00

USD

100.0

Treatment(s)

Add

Edit

Copy

Delete

Treatment Group A

Enrolled subjects: 260

FSFT/FPFT Date: 05/24/22

Enrollment period: 44 weeks

Enrollment rate: 1.66 s/s/m

Enrollment distribution: Acute

LSFT/LPFT Date: 03/27/23

LSLT/LPLT Date: 09/10/23

Screening period: 1 weeks

Screening visits per subject: 1

CRF pages/screened subject: 6

Screen failure rate: 23.08 %

Number of subjects to screen: 340

Cycle duration: 12 weeks

Visits per subject: 16

CRF pages per subject: 160

Number of cycles: 2

Subject diary pages: 10

QOL pages: 4

Pharmacoeconomic pages:

Subject drop rate:

Follow subjects for: 52 weeks

% completed subjects followed: 45.00 %

First follow-up occurs after: 0 weeks

Follow-up visits occur every: 4 weeks

Follow-up drop rate: 40.00 %

Pages per follow-up visit: 65

Pages per visit: 6

Pages per visit: 3

Total Subjects: 260

PASD: 09/01/21

FSFV: 05/17/22

LSFV: 03/20/23

FSFT: 05/24/22

LSFT: 03/27/23

FSLV: 11/06/23

LSLV: 09/08/24

If you do **not** require a supplemental CSR and 2nd DB Lock we recommend that you include any follow-up period assumptions within the Treatment Period and to NOT enter any values in the Follow-up period (You will need to adjust the default values to 0 for each follow-up field.

IMPORTANT! – KEY TAKE AWAYS
We recommend not planning a follow-up period in this scenario and subsequently you can leave this # of days to DB lock as is.

If you decide to enter a follow-up period in your plan than you will need to adjust the **# of days to DB lock** on the Data Tab to include this duration + the days from LSLV to DB Lock (+35 days)



5.9 Data Tab – If no Supplemental CSR is needed

Because ClearTrial assumes by default that a Supplemental CSR is needed for the 30 day safety - ClearTrial will default the initial DB Lock to include ALL the subject data within the treatment period and therefore defaults to occur after LAST SUBJECT LAST TREATMENT (not LPO or Last Subject Last Visit)

Timeline

Number of pages in the Investigator Brochure: 125

Days from LSLT/LPLT until Database Lock: 35

Database Lock date: 10/15/23

Days from Database Lock until Draft Report due: 63

Draft Report date: 12/17/23

Will there be a Supplemental CSR?: ☒ Yes ☐ No

Days from LSLV/LPLV until Database Lock (EOS): 35

Database Lock (EOS) date: 10/13/24

Days from Database Lock (EOS) until Draft Report (EOS) due: 63

Draft Report (EOS) date: 12/15/24

Days from Final CSR (EOS) to Study/Budget End: 14

Number of manuscripts: 0

Database Lock until Statistical Report due: 35

Stat Report date: 11/19/23

Database Lock until Final Report due: 91

Final Report date: 01/14/24

Reduce effort for Supplemental CSR by: 56.80 %

Days from Database Lock (EOS) until Statistical Report (EOS) due: 35

Stat Report (EOS) date: 11/17/24

Database Lock (EOS) until Final Report (EOS) due: 91

Final Report (EOS) date: 01/12/25

Study/Budget End date: 01/26/25

IMPORTANT!
If you do not require a supplemental CSR and 2nd DB Lock, AND you have added a follow-up period on the prior Treatment Tab - you will need to adjust this value for # of Days to DB Lock to include ALL subject data including any data collected during follow-up.

You will answer "No" to the is Supplemental CSR is needed.

IMPORTANT! – KEY TAKE AWAYS
We recommend not planning a follow-up period in this scenario and subsequently you can leave this # of days to DB lock as is.



Long-Term Follow-up Considerations

ClearTrial now includes the ability to adjust the Project Management default effort during long-term follow-up. The ClearTrial default is 75% reduction in oversight. Override this value in your Plan if you do not need any reduction in PM oversight to 0%

Reduce Project Management effort during Follow-up by: %

Number of newsletters:

Number of years to archive data:

Multiple Treatment Groups/Cohorts (up to 26)

Multiple Treatment Groups/Cohorts

Key Considerations

- ClearTrial supports modeling up to 26 treatment groups/cohorts to plan complex trials such as Comparator studies, Oncology/Immuno-oncology studies, Survival studies, ...etc.
- These multiple treatment arms can also represent Protocol Amendments and/or Extension arms (if not all subjects will continue treatment)

1. Select the initial treatment group and click “Copy” depending on the # of changes needed. You can also “Add” additional treatment groups, as needed.
2. Modify “Enrolled subjects” in treatment group A and group B.
3. Change the Name of the treatment group to easily identify or distinguish between varying treatments/cohorts.
4. Enter the treatment/cycle duration, depending on if there is 1 or more cycles.
5. Enter the CRFs and Visits per subject for the new treatment group.
6. Define the Follow-up period for the treatment group (if it differs)

Copy Treatment Group A if the treatment assumptions are similar – or Add a new treatment group (up to 26) if they vary widely

You can now name your Treatment Group's to easily identify each group

Adjust the treatment duration/assumptions and follow up duration/assumptions as needed

The screenshot displays the ClearTrial software interface for configuring multiple treatment groups. The interface is organized into a table-like structure with columns for 'Screening', 'Treatment', and 'Follow-Up' parameters. Two treatment groups are visible: 'Treatment A' and 'Treatment B'. Each group has its own set of parameters, including 'Enrolled subjects', 'Screening period', 'Screening visits per subject', 'CRF pages/screened subject', 'Treatment duration', 'Visits per subject', 'Number of cycles', 'Subject diary pages', 'QOL pages', 'Pharmacoeconomic pages', 'Subject drop rate', 'Follow subjects for', '% completed subjects followed', 'First follow-up occurs after', 'Follow-up visits occur every', 'Follow-up drop rate', 'CRF pages per follow-up visit', and 'Subject diary pages per visit'. The 'Total Subjects' summary at the bottom indicates a total of 200 subjects across both groups. Red callout boxes provide additional context: one points to the 'Copy' button, another points to the 'Treatment A' group name, and a third points to the 'Treatment duration' field.

Treatment(s)	Screening	Treatment	Follow-Up
<input type="checkbox"/> Treatment A	Screening period: 1 weeks Screening visits per subject: 1 CRF pages/screened subject: 6	Treatment duration: 26 weeks Visits per subject: 6 CRF pages per subject: 100 Number of cycles: 1 Subject diary pages: 0 QOL pages: 0 Pharmacoeconomic pages: 0	Follow subjects for: 4 weeks % completed subjects followed: 100.00 % First follow-up occurs after: 4 weeks Follow-up visits occur every: 4 weeks Follow-up drop rate: 37.00 % CRF pages per follow-up visit: 0 Subject diary pages per visit: 0
<input type="checkbox"/> Treatment B	Screening period: 1 weeks Screening visits per subject: 1 CRF pages/screened subject: 6 Screen failure rate: 9.09 % Number of subjects to screen: 110	Treatment duration: 26 weeks Visits per subject: 6 CRF pages per subject: 100 Number of cycles: 1 Subject diary pages: 0 QOL pages: 0 Pharmacoeconomic pages: 0	Follow subjects for: 4 weeks % completed subjects followed: 100.00 % First follow-up occurs after: 4 weeks Follow-up visits occur every: 4 weeks Follow-up drop rate: 37.00 % CRF pages per follow-up visit: 0 Subject diary pages per visit: 0

Total Subjects: 200

Timeline: PASD: 01/01/21, PSFV: 04/16/21, LSPV: 08/19/21, PSFT: 04/23/21, LSFT: 08/26/21, FSLT: 10/21/21, LSLT: 02/23/22, FSLV: 10/21/21, LSLV: 02/23/22

Multiple Treatment Groups/Cohorts

Key Considerations

- ClearTrial provides the ability to manage each Treatment Group/Cohort globally or by location.

Clicks - Do This

1. Select the Treatment Group and then click "Edit"
2. You will be on the SUBJECT Tab
3. Choose to manage the First Subject First Treatment date for this treatment group by Treatment or by Location
4. You can override the default spread of enrolled subjects per location for this treatment group.

1 Select Treatment A

2 Click Edit

3 Manage FSFT date: ☒ By Treatment ☐ Per Location
FSFT/PPFT Date: 04/23/21

4 Location-specific Assumptions

Location	# Subjects	FSFT Date	Enrollment Period	LSFT Date	Enrollment Rate
Canada	20	07/30/21	4 weeks	08/26/21	2.17
USA	80	04/23/21	18 weeks	08/26/21	0.48

Total Subjects: 100


Subjects are spread across locations by default according to the ratio of sites in that location to the total number of sites. You can override the default spread per location here.

You can also determine if you want to manage your FSFT date by treatment group OR by location

Dosing Escalation and Sequential Treatment Arms

MTD Trial Design

3 + 3 Phase 1 Study Design Schematic



MTD (Tolerability)
Assume no Toxicity

Group 1= 3 Subjects
Enrollment period is 2 weeks
Treatment period is 2 weeks
No Follow-up Period
May need to adjust drop rate

Pause to evaluate Patients (2 weeks)

Group 1= 3 Subjects
FPI Date is 2 weeks after
LSLT of Group 1
Enrollment period is 2 weeks
Treatment period is 2 weeks
No Follow-up Period
May need to adjust drop rate

Dose Escalation and Maximum Tolerable Dose (MTD) Trial Design

Phase I/II Study Design

- Relapsed or relapsed and refractory MM
- ≥ 2 prior lines of therapy
- Ineligible for ASCT

PART 1

Dose-
escalation
cohorts

Open label, weekly IV infusion, 8 weeks
Dose escalation: 3 + 3 scheme*
0.005 \rightarrow 0.05 \rightarrow 0.1 \rightarrow 0.5 \rightarrow 1.0 \rightarrow 2.0 \rightarrow 4.0 \rightarrow 8.0 \rightarrow 16.0 \rightarrow 24.0 mg/kg

PART 2


Expansion
cohorts

Ongoing
Several cohorts and dose schedules are being tested

* Start with predose at 10% of the full dose, maximum 10 mg; 3 weeks delay after first full dose

Lokhorst HM et al. *Proc ASCO* 2013;Abstract 8512.

Dose Escalation and Maximum Tolerable Dose (MTD) Trial Design



3+ treatment arms

Stratum 1 = 24 Subjects
Enrollment period is 12 weeks
Treatment period is 8 weeks
No Follow-up period

Pause to evaluate Patients (3 weeks)

Stratum 2 = 24 Subjects
FPI Date is 3 weeks after LSLT of Stratum 1
Enrollment period is 12 weeks
Treatment period is 8 weeks
No Follow up period

Pause to evaluate Patients (3 weeks)

Additional Dose Expansion Cohorts may be added

Stratum 3 = 48 Subjects
FPI date is 3 weeks after LSLT of Stratum 2
Enrollment period is 24
Treatment period is 4 weeks
Long Term Follow-up period is 12 weeks



Adaptive Trial Design Considerations

Does the protocol provide assumptions for Adaptive Trials Design assumptions?

- How many subjects per treatment arm?
- When Does Adaption Begin (defines FPI dates for Treatment Arms)
- Define duration of treatment and follow up details per arm.
- # of visits per treatment
 - Do Subjects enter long term follow-up?
 - What is the drop rate from the treatment period to the follow up period?
 - How frequency are the subject visits during the follow-up?
- Additional Considerations:
- Type of data collected per treatment arm (ePRO, Medibles, Wearables, Home Care Visits, other/lab?)

How to Plan Adaptive Trials in ClearTrial

Pro-actively Plan for the Adaptive Trial Design

- If the protocol provides enough detailed assumptions to properly estimate the “decision points” for how treatment may change across the group of subjects then plan using the Multiple Treatment Arms functionality on the Treatment Tab.
- Add the # of Treatment groups needed to properly estimate the total “in-life” portion of treatments. Note only 5 Treatment arms allowed in 5.8 but up to 26 arms allowed in our next release of 5.9. Flexible treatment scheduling is targeted to be released later this year.
- Allocate the total # of subjects per treatment arm and plan the “average” duration of treatment, average # of CRFS per treatment, average # of subject visits per treatment and other key assumptions (# of labs/treatment, subject diary pages/treatment, QOL pages/treatment)
 - Custom Fields allows you to add other essential elements such as:
 - # of images, # of ECGs, # of PK labs, # of specialty/biomarker labs, and other ancillary vendor costs drivers. These are then used in the Cost tab configurations to build out these ancillary vendor fees.
- Adjust the treatment schedule during study execution if needed.

How to Plan Adaptive Trials in ClearTrial

Reactively Plan for the Adaptive Trial Design (reforecast the plan)

- If the protocol does not provides enough detailed assumptions to properly estimate the “decision points” for how treatment may change across the group of subjects you can begin by planning the average treatment duration for ALL subjects in one (1) treatment group.
- Once the study is under way, you can adjust your plan (Copy Plan, and revise treatment) based on the revised treatment schedule (for all remaining patients, or for a subset of patients).
- Enter the # of subjects already enrolled in the initial treatment arm and adjust the schedule and assumptions based on “actuals”.
- Create one or more treatment groups for the remaining subjects based on the revised protocol treatment schedule.
- Adjust the treatment schedule during study execution if needed.

Extension or Open Label Trial Design Considerations

Is the extension portion of the study known up front prior to the initial study start?

- If yes – you can include the extension/open label portion of the study in the initial study budget and leverage the **Long Term Follow-up** capabilities as well as **Supplemental CSR** capabilities..
- Will All Sites participate in the extension study? If yes, adjust site start-up activities if needed. If no, this may indicate needing to create a 2nd Plan vs. including in this plan.
- Will All Subjects from the initial study continue into the extension study? If Yes, you can include them in the follow-up portion of the treatment arm and set the drop rate % to 0% dropped subjects. You will have an opportunity to set a drop rate % for the follow-up period separate from the treatment period if needed.
- If there are different treatment arms for the extension study you can create multiple treatment arms and label the treatment arms “Extension....” to easily define them. You will set the FPI date for the Extension study to begin after last subject finishes treatment (and follow-up) from the initial portion of the study.

Extension or Open Label Trial Design Considerations

Is the extension portion of the study known up front prior to the initial study start?

- If no – you can create a new “Plan” under the same “Study” for the extension portion of treatment, and select a pre-configured “Extension Study Template” that will scope the services automatically.
- Considerations:
 - Site Start-up is not required or reduced
 - Regulatory Support is reduced
 - DM Build/Setup is not required or reduced
 - Safety Build/Setup is not required or reduced
 - Biostats TLFs can be re-used (no unique TLFs)
 - Monitoring effort will adjust based on scope of data. Further adjustments can be made for complexity of data.

Extension Trial Planning

Talking Points

- Extension Study Templates can be created that pre-define the “efficiency factor %” for tasks that are carried over from the initial study that do not require the full “build”

Clicks - Do This

1. From the Labor tab, you can select a Major Task and click on the “Adjust Hours or Fees” button in the top right corner to adjust the % of effort/fees to be reduced for “repeat work”
2. You can see how the Fees and hours are adjusted by viewing the Calculated amounts and the Adjusted Amounts in the User Interface.

ORACLE
CLEARTRIAL PLAN AND SOURCE

Long Term Follow-up Study Template (Generic Sponsor)
Phase II
Indication: Other / Other (Routine)

This template is using the 5.8 cost model
This template is using custom fields, version 1
[View Template Errors...](#)

Edit Report Maintain Admin Help Welcome, Kristin Ludwig Visit Oracle Help Center Logout

Edit Template [Notes](#)

View or adjust effort and labor fees

Filter
Show hours and fees for: Medpace Sandbox ☒ Show major tasks with no planned effort for the selected provider

[New Major Task](#) [Edit Major Task](#) [Copy Major Task](#) [Delete Major Task](#) [Adjust Hours or Fees](#)

All calculated costs and adjustments are displayed in US Dollar (USD)

Major Task		Unit Hours	Unit Cost	# Units	Ext Hours	Ext Cost
Study Setup	Calculated	122.426	26,249.28	1	122.426	26,249.28
	Adjusted	61.213	13,124.64	1	61.213	13,124.64
Protocol Development	Calculated	31.000	6,514.75	1	31.000	6,514.75
	Adjusted	15.500	3,257.37	1	15.500	3,257.37
Unique CRF Page Developed	Calculated	15.400	2,935.89	10	154.000	29,358.90
	Adjusted	6.160	1,174.35	10	61.600	11,743.50
Meetings - Investigator Meeting		0.000	0.00	0	0.000	0.00
Meetings - Kickoff Meeting		0.000	0.00	0	0.000	0.00
TMDR Review		0.000	0.00	1	0.000	0.00
Total Hours/Fees:	Calculated:				17,145.055	3,066,034.19
	Adjusted:				12,599.968	2,225,417.84

[Close](#) [Save](#) [Next](#)

Extension Trial Planning

Talking Points

- Adjusting Hours and Fees (Top line adjustment)
- Can be done easily by clicking on the Major Task, and clicking “Adjust fees and Hours button”)
- A new window will open to allow you to view, expand and adjust the Unitized assumptions as needed
- For example adjust hours by 50% will automatically adjust the hours and the fees.

Clicks - Do This

1. When the new window opens, you can view the roll up of the Hours and Fees, to make adjustments, click on the “Expand all” link and the fields will display for you to override the
 - Units
 - Hours or hour %
 - Fees or Fee %

The screenshot displays the Task Manager interface for 'Safety database Development'. The 'Adjustments' tab is selected, and the 'Expand All' button is highlighted with a red box and an arrow labeled '1'. Below, the 'Study Setup' window is shown with the 'Unit Hours' field set to 50% and the 'Extended Hours' field set to 61,213. The 'Extended Cost' is also updated to 13,124.64.

Location	Planned	+/-	Adjusted	Pinned
Centralized	Extended Hours: 39,000		15,600	
	Extended Cost: 7,802.25		3,120.90	

Location	# Units	Unit Hours	Unit Cost	Extended Hours	Extended Cost
Centralized	1	122,426	26,249.28	61,213	13,124.64

Umbrella/Bucket Study Considerations

Will Subjects come into this Umbrella study that will continue on different durations of treatment?

- If yes – create multiple treatment groups for each treatment duration and adjust screening assumptions to 0%, and adjust follow-up period and drop rates as needed.
- If no – you can create a new “Plan” under the same “Study” for the extension portion of treatment, and select a pre-configured “Extension Study Template” that will scope the services automatically.
- Considerations:
 - Are the sites already activated and participating in the study?
 - Site Start-up is not required or reduced
 - Regulatory Support is reduced
 - DM Build/Setup is not required or reduced
 - Safety Build/Setup is not required or reduced
 - Biostats TLFs can be re-used (no unique TLFs)
 - Monitoring effort will adjust based on scope of data. Further adjustments can be made for complexity of data.

Questions?